Novel Bispecific Antibody Drug IVONESCIMAB AKESO Shows Significant Efficacy In Multiple Solid Tumors
Guangzhou, China, October 15, 2023 – Ivonescimab Akeso (Kangfang Bio, HKEX: 9926.HK) today announced the latest clinical trial of its self-developed bispecific antibody drug Ivonescimab(R&D code: AK112).
The drug has demonstrated significant anti-tumor activity in the treatment of several solid tumors, bringing new hope to cancer patients.
Ivonescimab Akeso is a bispecific antibody targeting PD-1 and VEGF. It achieves dual anti-tumor effects by simultaneously blocking the PD-1 immune checkpoint and VEGF angiogenic pathway, enhancing the tumor-killing effect of the immune system and inhibiting tumor angiogenesis.
This innovative mechanism enables it to demonstrate potential therapeutic advantages in a wide range of solid tumors.
About Ivonescimab Akeso
AKESO (Kangfang Bio) is a biopharmaceutical company dedicated to the development, production and commercialization of innovative antibody drugs.
With a world-leading bispecific antibody development platform and a number of innovative drugs in the clinical stage, Ivonescimab Akeso is committed to improving the quality of life of patients around the world through innovative medicines.
Ivonescimab Clinical Data Highlights
In the newly announced Phase II clinical trial, Ivonescimab monotherapy in non-small cell lung cancer (NSCLC) achieved an objective remission rate (ORR) of 45.6% and a disease control rate (DCR) of 82.3%.
The Ivonescimab drug also demonstrated significant anti-tumor activity in patients with advanced cervical and colorectal cancers, with ORRs of 38.7% and 33.5%, respectively.
Akeso Chief Medical Officer said, “The clinical data of Ivonescimab is encouraging, especially in patients who are resistant to PD-1 monotherapy, the drug still demonstrates significant efficacy.
This provides a new option for those patients for whom traditional treatment options have failed.”
Safety Performance
In terms of safety, Ivonescimab demonstrated good tolerability.
Ivonescimab Akeso Common adverse reactions included fatigue, hypertension and proteinuria, all of which were manageable with no serious immune-related adverse events.
Future Outlook
Ivonescimab Akeso plans to initiate a global multicenter Phase III clinical trial of Ivonescimab in 2024 to further validate its efficacy and safety in multiple solid tumors
The Company also plans to communicate with regulatory agencies such as the U.S. FDA and the European EMA to accelerate the global Ivonescimab FDA approval.
Dr. Yu Xia, Founder and CEO of Ivonescimab, said, “Ivonescimab Akeso is one of the key achievements of AKESO’s innovative drug discovery platform.
We believe that Ivonescimab drug is expected to become an important breakthrough in the global cancer treatment field and provide more effective treatment options for patients.”
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.
We welcome you to reach out to us to buy Ivonescimab ASCO. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
